Research Analysts’ Weekly Ratings Changes for Invivyd (IVVD)

A number of firms have modified their ratings and price targets on shares of Invivyd (NASDAQ: IVVD) recently:

• 12/29/2025 – Invivyd had its “sell (e+)” rating reaffirmed by analysts at Weiss Ratings.
• 12/22/2025 – Invivyd had its “sell (e+)” rating reaffirmed by analysts at Weiss Ratings.
• 12/22/2025 – Invivyd is now covered by analysts at BTIG Research. They set a “buy” rating and a $10.00 price target on the stock.
• 12/22/2025 – Invivyd is now covered by analysts at BTIG Research. They set a “buy” rating and a $10.00 price target on the stock.
• 12/15/2025 – Invivyd had its “sell (e+)” rating reaffirmed by analysts at Weiss Ratings.
• 12/8/2025 – Invivyd had its “sell (e+)” rating reaffirmed by analysts at Weiss Ratings.
• 12/2/2025 – Invivyd had its “sell (e+)” rating reaffirmed by analysts at Weiss Ratings.
• 11/26/2025 – Invivyd had its “sell (e+)” rating reaffirmed by analysts at Weiss Ratings.
• 11/25/2025 – Invivyd was downgraded by analysts at D Boral Capital from a “strong-buy” rating to a “hold” rating.
• 11/25/2025 – Invivyd had its “hold” rating reaffirmed by analysts at D. Boral Capital.
• 11/13/2025 – Invivyd was upgraded by analysts at Zacks Research from a “strong sell” rating to a “hold” rating.

Insider Buying and Selling at Invivyd

In other Invivyd news, Director Kevin F. Mclaughlin bought 50,000 shares of the firm’s stock in a transaction dated Wednesday, November 19th. The shares were purchased at an average cost of $2.50 per share, for a total transaction of $125,000.00. Following the transaction, the director owned 50,000 shares of the company’s stock, valued at $125,000. This represents a ∞ increase in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Company insiders own 25.40% of the company’s stock.

Invivyd, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of antibody-based solutions for infectious diseases in the United States. The company developed INVYMAB, a platform that combines viral surveillance and predictive modeling with advanced antibody engineering. Its pipeline includes PEMGRADA (pemivibart) injection, a half-life extended investigational monoclonal antibody (mAb) for the prevention of COVID-19 in adults and adolescents; VYD2311, an mAb candidate which is in preclinical studies for the prevention or treatment for COVID-19; and adintrvimab, that is in phase 3 clinical trials for the prevention or treatment of COVID-19.